Key result
Genetics advances LQTS mechanisms and enables gene-specific management but overall treatments remain largely unchanged.
Why the study?
To summarize and critically assess the contribution of genetics to LQTS, specifically regarding underlying mechanisms and clinical practice impact.
What is the impact of genetics on the mechanistic understanding and clinical management of Long QT Syndrome?
What is the impact of genetics on the mechanistic understanding and clinical management of Long QT Syndrome?
Answers are grounded in this paper and cite their sources.
While genetics has vastly improved the mechanistic understanding and risk stratification of LQTS, core therapeutic approaches remain largely unchanged from the pregenetic era.
PURPOSE OF REVIEW: To summarize and critically assess the contribution of genetics to the Long QT Syndrome (LQTS), with specific reference to the unraveling of its underlying mechanisms and to its impact on clinical practice. RECENT FINDINGS: The evolution towards our current approach to therapy for LQTS patients is examined in terms of risk stratification, gene-specific management, and assessment of the clinical impact that genetic modifiers may have in modulating the natural history of the patients. Glimpses are provided on the newest multidisciplinary approaches to study disease mechanisms, test new candidate drugs and identify precision treatments. SUMMARY: It is undeniable that genetics has revolutionized our mechanistic understanding of cardiac channelopathies. Its impact has been enormous but, curiously, the way LQTS patients are being treated today is largely the same that was used in the pregenetic era, even though management has been refined and gene-specific differences allow a more individually tailored antiarrhythmic protection. The synergy of genetic findings with modern in vitro and in silico tools may expand precision treatments; however, they will need to prove more effective than the current therapeutic approaches and equally safe.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2023) conducted a review in Long QT Syndrome (LQTS). Genetics and precision treatments was evaluated. Genetics has revolutionized the mechanistic understanding of Long QT Syndrome, allowing for gene-specific management, though overall treatment approaches remain largely similar to the pregenetic era.
Synapse has enriched 10 related papers. Consider them for comparative context: